Antibacterial properties of the CFTR potentiator ivacaftor

Foundation CF, 2011 Van Goor, 2009, Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770, Proc Natl Acad Sci U S A, 106, 18825, 10.1073/pnas.0904709106 Accurso, 2010, Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation, N Engl J Med, 363, 1991, 10.1056/NEJMoa0909825 Heeb, 2011, Quinolones: from antibiotics to autoinducers, FEMS Microbiol Rev, 35, 247, 10.1111/j.1574-6976.2010.00247.x 2012 Pezzulo, 2012, Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung, Nature, 487, 109, 10.1038/nature11130 Becher, 2000, Integration-proficient Pseudomonas aeruginosa vectors for isolation of single-copy chromosomal lacZ and lux gene fusions, Biotechniques, 29, 948, 10.2144/00295bm04 West, 1994, Construction of improved Escherichia–Pseudomonas shuttle vectors derived from pUC18/19 and sequence of the region required for their replication in Pseudomonas aeruginosa, Gene, 148, 81, 10.1016/0378-1119(94)90237-2 Zhang, 2000, Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa, Antimicrob Agents Chemother, 44, 3317, 10.1128/AAC.44.12.3317-3321.2000 Wong, 2013, Staphylococcus aureus in early cystic fibrosis lung disease, Pediatr Pulmonol, 48, 1151, 10.1002/ppul.22863 An, 2013, Linezolid versus vancomycin for meticillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials, Int J Antimicrob Agents, 41, 426, 10.1016/j.ijantimicag.2012.12.012 Raggio, 2012 Travis, 1999, Activity of abundant antimicrobials of the human airway, Am J Respir Cell Mol Biol, 20, 872, 10.1165/ajrcmb.20.5.3572 Nikaido, 1985, Molecular basis of bacterial outer membrane permeability, Microbiol Rev, 49, 1, 10.1128/MMBR.49.1.1-32.1985 Vaara, 1992, Agents that increase the permeability of the outer membrane, Microbiol Rev, 56, 395, 10.1128/MMBR.56.3.395-411.1992 Kelly, 1984, Antibiotic use in cystic fibrosis, Drug Intell Clin Pharm, 18, 772, 10.1177/106002808401801001 Doring, 2004, Early intervention and prevention of lung disease in cystic fibrosis: a European consensus, J Cyst Fibros, 3, 67, 10.1016/j.jcf.2004.03.008 Seddon, 1980, Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin, Antimicrob Agents Chemother, 18, 240, 10.1128/AAC.18.2.240 Frei, 2010, Trimethoprim–sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections, J Am Board Fam Med, 23, 714, 10.3122/jabfm.2010.06.090270 Chu, 1989, Structure–activity relationships of the fluoroquinolones, Antimicrob Agents Chemother, 33, 131, 10.1128/AAC.33.2.131 Andriole, 2005, The quinolones: past, present, and future, Clin Infect Dis, 41, S113, 10.1086/428051 Cook, 1995, Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments, J Antimicrob Chemother, 35, 317, 10.1093/jac/35.2.317